The drug received full approval this month, opening the doors to Medicare payments and expanding access for Alzheimer's patients who qualify for the twice-monthly infusion treatment.
that its treatment, donanemab, showed a 35% reduction in cognitive decline, or about seven-and-a-half months of slowing disease progression.
"We're expecting that Leqembi is also going to work in even earlier stage patients than where we are," Scott said. In fact, the lessons learned from Aduhelm's failure helped Eisai navigate the process. That includes knowing that Medicare would place restrictions on anything but a full, traditional approval.
It's why the company chose the price point it did and filed for full approval in order to get more potential patients on its drug.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
The Medicare Behemoth Finally Smiles on Primary CareNew care models aim to reduce the primary care-specialist pay gap.
Baca lebih lajut »
Weekend guide: Kick off 'Flirty Friday' at new restaurant's opening, or explore new Asian exhibitIt's the weekend! You could kick off 'Flirty Friday' at this restaurant's grand opening, journey through a free exhibit showcasing five different Asian countries, and so much more.
Baca lebih lajut »
New Jersey sues over New York City's congestion pricing plan | CNN BusinessNew Jersey is suing to stop New York City’s landmark congestion price plan to charge drivers entering downtown Manhattan.
Baca lebih lajut »
The New York Times’ New Hit Game Has a Problem Wordle Never DidI solve the puzzle often. I'm not so sure that's a good thing.
Baca lebih lajut »